Clearstead Advisors, LLC Recursion Pharmaceuticals, Inc. Transaction History

Clearstead Advisors, LLC

$6.94 Billion
Q2 2025

A detailed history of Clearstead Advisors, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 5,738 shares of RXRX stock, worth $31,673. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,738

Previous 400 1334.5%

Holding current value

$31,673

Previous $2,000 1350.0%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 08, 2025	SELL	$3.97 - $5.84 $480 - $706	-121 Reduced 2.07%	5,738 $29,000
Q1 2025 May 13, 2025	BUY	$5.29 - $10.87 $30,994 - $63,687	5,859 New	5,859 $30,000
Q3 2024 Nov 13, 2024	BUY	$5.92 - $8.6 $2,220 - $3,225	375 Added 300.0%	500 $3,000
Q2 2024 Aug 09, 2024	SELL	$7.35 - $10.05 $735 - $1,005	-100 Reduced 44.44%	125 $0
Q1 2024 May 14, 2024	BUY	$9.13 - $15.52 $913 - $1,552	100 Added 80.0%	225 $2,000
Q3 2023 Nov 07, 2023	BUY	$6.59 - $15.86 $823 - $1,982	125 New	125 $0

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $996M
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.

Account

Clearstead Advisors, LLC Recursion Pharmaceuticals, Inc. Transaction History